| Properties | Information | |
|---|---|---|
| PhytoCAT-ID | PhytoCAT-1481 | |
| Phytochemical name or plant extracts | Chrysin | |
| PMID | 26578185 | |
| Literature evidence | Most free flavones (26-28 and 30) showed significant cytotoxic activities at 10 μM (up to 61.2% inhibition rate). | |
| IUPAC name | 5,7-dihydroxy-2-phenylchromen-4-one | |
| Phytochemicals’ class or type of plant extracts | Flavonoid | |
| Source of phytochemicals or plant Extracts | Scutellaria baicalensis | |
| Geographical availability | Amur, Buryatiya, China North-Central, China South-Central, Chita, Inner Mongolia, Irkutsk, Khabarovsk, Korea, Manchuria, Mongolia, Primorye, Vietnam, Yakutskiya | |
| Plant parts | Root | |
| Other cancers | Breast cancer, Colon cancer, Liver cancer, Cervical cancer, Skin cancer, Lung Cancer, Leukemia | |
| Target gene or protein | BRCA1, FTO, H2AX, MMP2, MMP9, RAD51, STAT-3, Aromatase | |
| Gene or Protein evidence | Chrysin analog CHM-09 and known EGFR inhibitors demonstrated a comparable anti-proliferative, anti-migratory activity along with the induction of apoptosis and cell cycle arrest in MDA-MB-231. The results of Real-time PCR suggested that encapsulated chrysin have higher antitumor effect on gene expression of FTO, BRCA1 and hTERT than free chrysin, the combination treatment for 36 h synergistically decreased MDA-MB-231 cell motility but not cell viability through down-regulation of MMP2, MMP9, fibronectin, and snail in MDA-MB-231 cells. Chrysin has potency in inhibition of the aromatase enzyme and thus can be useful in preventing and treating the hormone-dependent breast cancer and as an adjuvant therapy for estrogen-dependent diseases. | |
| Target pathways | ATM-Chk2 pathway Akt signal pathway Matrix metalloproteinase-10, epithelial to mesenchymal transition, and PI3K/Akt signaling pathway | |
| IC50 | BCRP-overexpressing human 0.39 µM against MCF-7 10 ± 4 µM against MV4-11 | |
| Potency | This study demonstrated that free flavones showed potent anti-influenza, anti-cancer and anti-oxidative activities. | |
| Cell line/ mice model | MCF-7, BT-474, HeLa, HepG-2, MDA-MB-468, BCRP-MDCKII, Caco-2, 518A2, HCT-116 colon, KB-V1/Vbl cervix, MCF-7/Topo, MDA-MB-231, A549 , T47D, MV4-11, LoVo | |
| Additional information | Increases ROS levels in MCF-7 cells Increases p53 protein expression and the p53-mediated expression of downstream target genes Combined with apigenin, suppresses tumor growth in human MDA-MB-231 breast cancer cells xenograft through down-regulation of ki-67 and Skp2 protein potent inhibitor of BCRP, has the potency of aromatase inhibition Induces increased E-cadherin expression and decreased expression of vimentin, snail and slug in TNBC cells - thus, exhibiting a reversal effect on epithelial-mesenchymal transition Acts as a potent inhibitor of P-gp, MRP-2, and BCRP in Caco-2 colon carcinoma cells. Apigenin plus chrysin induces apoptosis through down-regulation of S-phase kinase-associated protein-2 (Skp2) and low-density lipoprotein receptor-related protein 6 (LRP6) expression Combination of chrysin and metformin significantly decreases cyclin D1 and hTERT gene expression in the T47D breast cancer cell line 9. Decreases the uptake of GHB in rat MCT1 gene-transfected MDA-MB231 cells | |
| PubChem ID | 5281607 | |
| Additional PMIDs | 34985375 21899551 29890668 17948189 27137679 17093006 32181408 19666078 31493543 24122885 20457140 23973682 30774307 26670842 27137679 27847208 32364671 29693804 24122885 27847208 27847208 19576743 34985375 27137679 31491838 27470413 27761071 | |
| Additional sources of information | https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:458155-1 | |
| Safety | NA |